Combination Product

« Back to Glossary Index

What it is

Combination Product is a single product or a matched set that combines two or more regulated components (for example, drug + device or biologic + device). In the U.S., FDA defines categories such as single-entity, co-packaged, and cross-labeled combination products (21 CFR 3.2(e)); oversight follows the component with the product’s primary mode of action (PMOA). In the EU, drug–device combinations are handled under MDR/medicinal product rules, including integral products and devices that incorporate an ancillary medicinal substance (MDR 2017/745 Art. 1(8)–(9); Annex VIII Rule 14; Article 117).

Mixed modalitiesPMOA-based oversightLifecycle compliance

Regulatory framework

  • US (FDA): Definition and assignment (21 CFR 3.2(e); FD&C Act; PMOA per 21 CFR 3.2(m)); Office of Combination Products (OCP) assigns lead center (CDER/CBER/CDRH); CGMPs for combo products (21 CFR Part 4) bridging drug cGMPs (21 CFR 210/211), device QSR/QMSR (21 CFR 820), and biologics (21 CFR 600–680); premarket pathways depend on PMOA (e.g., NDA/BLA/510(k)/PMA/De Novo).
  • EU (MDR + Medicinal law): Devices incorporating an ancillary medicinal substance (MDR Art. 1(8), Annex IX Rule 14) require Notified Body assessment with medicinal authority consultation; medicinal products presented with a device as an integral product require evidence of device conformity within the marketing authorization (MDR Art. 1(9); Article 117 adds device evidence to the MA dossier; device GSPRs per MDR Annex I).
  • Canada: Drug–device combination classified per primary purpose under the Food and Drugs Act and Medical Devices Regulations; coordination between branches; MDSAP for QMS where device rules apply.
  • Japan (PMDA/MHLW): PMD Act applies based on primary function; combo review coordinates drug, device, and biologic offices; GVP/QMS ordinances (MHLW Ord. No. 135/2004; No. 169/2004).
  • Australia (TGA): Therapeutic Goods Act/Regulations; classification and sponsor obligations depend on principal intended action; ARTG inclusion with evidence covering both components.

Key elements

  • PMOA: The single mode of action providing the most important therapeutic effect determines the lead legal pathway.
  • Category: Single-entity, co-packaged, or cross-labeled (US; 21 CFR 3.2(e)).
  • Standards & GxPs: Bridging of drug cGMP, device QMS (QMSR/ISO 13485), and biologics GMP, as applicable (21 CFR Part 4).
  • Evidence: Quality, nonclinical, and—when needed—clinical data showing safety, performance, and benefit-risk across all components.
  • Labeling & UDI: Clear, consistent claims; device UDI and drug labeling rules both observed where required.

Process — how it works

  • Determine PMOA: First, identify the principal therapeutic action to choose the lead pathway; if unclear, request a Request for Designation (RFD) (US; 21 CFR Part 3).
  • Map obligations: Then, list drug, device, and (if relevant) biologic requirements including CGMP/QMS, stability, sterility, and biocompatibility.
  • Plan evidence: Build an integrated plan for quality, performance, and clinical data aligned to intended use and claims.
  • Prepare dossier: Compile the lead application (e.g., NDA/BLA/510(k)/PMA) and include the required bridging information (e.g., 21 CFR Part 4 compliance summary; EU Article 117 device evidence in MA file).
  • Review & approval/conformity: Undergo coordinated review (e.g., FDA OCP-assigned center with consults; EU NB plus medicines authority consult).
  • Post-market: Finally, implement PMS and vigilance covering all components (e.g., 21 CFR 803/806 for devices; drug safety reporting rules; MDR Arts. 83–92 in the EU).

Common pitfalls

  • Misidentifying PMOA, which leads to the wrong pathway and delays.
  • Ignoring 21 CFR Part 4; quality systems must bridge drug and device requirements.
  • Weak Article 117 packages for EU medicinal applications that include an integral device.
  • Claims that split or contradict between drug and device labeling.
  • PMS that tracks only one component, therefore missing cross-signals.

Quick checks

  • Is PMOA clearly justified and documented? If not, consider an RFD (US).
  • Does the QMS show how drug cGMP and device QMSR/ISO 13485 interact (21 CFR Part 4)?
  • For EU, does the MA dossier include device evidence or NB opinion per Article 117 when needed?
  • Are risk management and labeling consistent across components and markets?

FAQ

What is a combination product in the U.S.?

It is a product made of two or more regulated components—drug, device, and/or biologic—defined in 21 CFR 3.2(e) as single-entity, co-packaged, or cross-labeled.

Who reviews a U.S. combination product?

FDA’s Office of Combination Products assigns a lead center based on PMOA; other centers consult as needed (21 CFR Part 3).

Which quality rules apply?

21 CFR Part 4 requires a streamlined approach that satisfies both drug cGMP (21 CFR 210/211) and device QMS (21 CFR 820/QMSR), as applicable.

How are EU drug–device combinations handled?

Devices with an ancillary medicinal substance follow MDR with medicines authority consultation (MDR Art. 1(8)); integral products in a medicinal MA require device evidence per Article 117.

How should we manage post-market events?

Trend and report under all applicable systems: device vigilance (e.g., 21 CFR 803; MDR Arts. 87–92) and medicinal product pharmacovigilance, then align CAPA across components.